Sorafenib in advanced hepatocellular carcinoma

New England Journal of Medicine

Volumn 359, Issue 4, 2008, Pages 378-390

  Llovet, Josep M ^a,b,w   Ricci, Sergio ^c   Mazzaferro, Vincenzo ^d   Hilgard, Philip ^e   Gane, Edward ^f   Blanc, Jean Frédéric ^g   De Oliveira, Andre Cosme ^h   Santoro, Armando ⁱ   Raoul, Jean Luc ^j   Forner, Alejandro ^a   Schwartz, Myron ^b   Porta, Camillo ^k   Zeuzem, Stefan ^l   Bolondi, Luigi ^m   Greten, Tim F ⁿ   Galle, Peter R ^o   Seitz, Jean François ^p   Borbath, Ivan ^q   Häussinger, Dieter ^r   Giannaris, Tom ^s   Shan, Minghua ^t   Moscovici, Marius ^u   Voliotis, Dimitris ^v   Bruix, Jordi ^a,w   more..

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PISA   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

^f AUCKLAND CITY HOSPITAL   (New Zealand)

^g HÔPITAL SAINT ANDRÉ   (France)

^h UNIVERSITY OF SÃO PAULO   (Brazil)

ⁱ HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^j European University in Brittany   (France)

^k FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^l UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^m UNIVERSITY OF BOLOGNA   (Italy)

ⁿ HANNOVER MEDICAL SCHOOL   (Germany)

^o JOHANNES GUTENBERG UNIVERSITY   (Germany)

^p TIMONE HOSPITAL   (France)

^q CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^r UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^s Bayer HealthCare Pharmaceuticals   (Canada)

^t BAYER CORPORATION   (United States)

^u Bayer Schering Pharma   (Italy)

^v BAYER PHARMA AG   (Germany)

^w HOSPITAL CLÍNIC   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SORAFENIB;

ABDOMINAL PAIN; ADULT; ALOPECIA; ANOREXIA; ARTICLE; ASCITES; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ESOPHAGUS VARICES BLEEDING; FATIGUE; FEMALE; HAZARD RATIO; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPOPHOSPHATEMIA; KIDNEY FAILURE; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SKIN EXFOLIATION; SKIN MANIFESTATION; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT REDUCTION;

EID: 47949116252     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0708857     Document Type: Article

References (35)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-17.
3. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36.
4. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001;35:421-30.
5. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429-42.
6. Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma - an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 2006;23:1535-47.
7. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109.
8. Chang YS, Adnane J, Trail PA, et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 2007;59:561-74.
9. Ito Y, Sasaki Y, Horimoto M, et al. Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology 1998;27:951-8.
10. Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007;27:55-76.
11. Calvisi DF, Ladu S, Gorden A, et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 2006;130:1117-28.
12. Semela D, Dufour JF. Angiogenesis and hepatocellular carcinoma. J Hepatol 2004;41:864-80.
13. Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006;66:11851-8.
14. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:4293-300.
15. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
16. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9.
17. Child CG III, ed. The liver and portal hypertension. Vol. 1 of Major problems in clinical surgery. Philadelphia: W.B. Saunders, 1964:50-64.
18. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
19. Yount S, Cella D, Webster K, et al. Assessment of patient-reported clinical outcome in pancreatic and other hepatobiliary cancers: the FACT Hepatobiliary Symptom Index. J Pain Symptom Manage 2002;24:32-44.
20. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979;35:549-56.
21. Yeo W, Mok TS, Zee B, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005;97:1532-8.
22. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-50.
23. Martínez Cerezo FJ, Tomás A, Donoso L, et al. Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma. J Hepatol 1994;20:702-6.
24. Lai CL, Lau JY, Wu PC, et al. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology 1993;17:389-94.
25. Philip PA, Mahoney MR, Allmer C, et al. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005;23:6657-63.
26. Thomas MB, Chadha R, Iwasaki M, Glover K, Abbruzzese JL. The combination of bevacizumab (B) and erlotinib (E) shows significant biological activity in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2007;25:Suppl:214s. abstract.
27. O'Dwyer PJ, Giantonio BJ, Levy DE, Kauh JS, Fitzgerald DB, Benson AB III. Gefitinib in advanced unresectable hepatocellular carcinoma: results from the Eastern Cooperative Oncology Group's Study E1203. J Clin Oncol 2006;24:Suppl:213s. abstract.
28. Schwartz JD, Schwartz M, Lehrer D, et al. Bevacizumab in unresectable hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein. J Clin Oncol 2006;24:Suppl:213s. abstract.
29. Zhu AX, Blaszkowsky LS, Ryan DP, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:1898-903.
30. Faivre SJ, Raymond E, Douillard J, et al. Assessment of safety and drug-induced tumor necrosis with sunitinib in patients (pts) with unresectable hepatocellular carcinoma (HCC). J Clin Oncol 2007;25:Suppl:149s. abstract.
31. Zhu AX, Sahani DV, di Tomaso E, et al. A phase II study of sunitinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2007;25:Suppl:231s. abstract.
32. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34. [Erratum, N Engl J Med 2007;357:203.]
33. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505-12.
34. Wood LS. Managing the side effects of sorafenib and sunitinib. Community Oncol 2006;3:558-62.
35. Llovet JM, DiBisceglie A, Bruix J, et al. Design and end-points of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100:698-711.